PlaqueTec is pursuing a better understanding of the biological mechanisms of atherosclerotic cardiovascular disease to advance the development of precision medicine. Atherosclerotic disease causes plaque build-up that narrows or blocks the arteries that supply blood to the heart, brain and limbs, and is a leading cause of death globally. Current treatment approaches are largely one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will support drug development by identifying new targets in specific patient groups, reducing clinical trial sizes and costs, and increasing success rates, ultimately improving outcomes for patients.
PlaqueTec: Venture Capital Funding History
PlaqueTec
PlaqueTec
- Health
- Cambridge, United Kingdom
- £3.7m
- plaquetec.com
- Update Information
More venture news
- 16 Nov 2026

ZyaZya lands a £12m Series A round led by Astanor to turn sugar in food into prebiotic fibre
Series AHealth - 4 Nov 2026

SurghiveSurghive raises a £320k seed round led by SFC Capital to train surgeons on any robotic surgery system
SeedHealth - 3 Nov 2026

1nhaler1nhaler lands a £2m follow-on round led by Archangels to test its pop-up cardboard asthma inhaler in patients
Follow-onHealth
